ZA961696B - Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders. - Google Patents

Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders.

Info

Publication number
ZA961696B
ZA961696B ZA9601696A ZA961696A ZA961696B ZA 961696 B ZA961696 B ZA 961696B ZA 9601696 A ZA9601696 A ZA 9601696A ZA 961696 A ZA961696 A ZA 961696A ZA 961696 B ZA961696 B ZA 961696B
Authority
ZA
South Africa
Prior art keywords
pyrrolopyrimidines
pyrazolopyrimidines
neuronal
disorders
treatment
Prior art date
Application number
ZA9601696A
Other languages
English (en)
Inventor
Yhpyng L Chen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA961696B publication Critical patent/ZA961696B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA9601696A 1995-03-02 1996-03-01 Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders. ZA961696B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39752795A 1995-03-02 1995-03-02

Publications (1)

Publication Number Publication Date
ZA961696B true ZA961696B (en) 1997-09-01

Family

ID=23571548

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9601696A ZA961696B (en) 1995-03-02 1996-03-01 Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders.

Country Status (11)

Country Link
EP (1) EP0729758A3 (de)
JP (1) JPH08259567A (de)
KR (1) KR960033454A (de)
CN (1) CN1065535C (de)
AU (1) AU715380B2 (de)
CA (1) CA2170700C (de)
IL (1) IL117229A (de)
MX (1) MX9600832A (de)
MY (1) MY140557A (de)
NZ (1) NZ286103A (de)
ZA (1) ZA961696B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
ES2191183T3 (es) * 1996-08-06 2003-09-01 Pfizer Derivados 6,6- o 6,7-biciclicos que contienen pirido o pirimido sustituidos.
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
WO1998035967A2 (en) * 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
PT896822E (pt) * 1997-08-05 2003-07-31 Pfizer Prod Inc 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
PL204628B1 (pl) * 1998-06-02 2010-01-29 Osi Pharmaceuticals Pochodna pirolo[2,3d]pirymidyny, jej zastosowanie i sposoby wytwarzania tej pochodnej i preparaty farmaceutyczne
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6159943A (en) * 1999-09-24 2000-12-12 Bioenergy, Inc. Use of ribose to prevent cramping and soreness in muscles
DE60026155T2 (de) 1999-09-30 2006-08-10 Neurogen Corp., Branford Einige alkylendiamin-substituierte heterocyclen
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
CA2398956A1 (en) * 2000-02-14 2001-08-16 Japan Tobacco Inc. A pharmaceutical composition for prophylaxis or therapy of a postoperative stress
DE10042092A1 (de) * 2000-08-26 2002-03-07 Dresden Arzneimittel Antikonvulsiv wirkende 2,5-Dihydro-pyrazolo(3,4-d)pyrimidin-4-one und Verfahren zu deren Darstellung
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
EP1450811B1 (de) 2001-11-30 2009-10-21 OSI Pharmaceuticals, Inc. Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
CA2471059C (en) 2001-12-20 2011-04-26 Osi Pharmaceuticals, Inc. Pyrimidine a2b selective antagonist compounds, their synthesis and use
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
JP2007502772A (ja) 2003-08-15 2007-02-15 メルク　エンド　カムパニー　インコーポレーテッド ４−シクロアルキルアミノピラゾロピリミジンｎｍｄａ／ｎｒ２ｂ拮抗薬
CN1910190A (zh) 2004-01-06 2007-02-07 大正制药株式会社 环氨基取代的噻吩并嘧啶和噻吩并吡啶衍生物
CA2552503C (en) * 2004-01-06 2011-09-13 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine and pyrrolotriazine derivatives
BRPI0709699A2 (pt) * 2006-03-29 2011-07-26 Foldrx Pharmaceuticals Inc inibiÇço da toxidez da alfa-sinucleina
EP2004656B1 (de) 2006-04-07 2013-07-10 Boehringer Ingelheim International GmbH Thienopyrimidine mit mnk1/mnk2-hemmender wirkung für pharmazeutische zusammensetzungen
EP1889847A1 (de) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidine zur pharmazeutischen Anwendung
US9555032B2 (en) 2007-06-13 2017-01-31 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling
EP2219649A2 (de) * 2007-11-22 2010-08-25 Boehringer Ingelheim International Gmbh Verwendung von mnk-inhibitoren zur behandlung von alzheimer-krankheit
KR20110045019A (ko) 2008-08-26 2011-05-03 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물을 위한 티에노피리미딘
AU2011219764A1 (en) 2010-02-26 2012-08-16 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
TW201141872A (en) 2010-02-26 2011-12-01 Boehringer Ingelheim Int Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
JP6082397B2 (ja) 2011-09-30 2017-02-15 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． マクロ環状ｌｒｒｋ２キナーゼ阻害剤
CN103864653A (zh) * 2012-12-10 2014-06-18 韩冰 一类降低眼压的化合物及其用途
CN103864797A (zh) * 2012-12-10 2014-06-18 韩冰 一类具有神经保护作用的化合物及其用途
PL3194405T3 (pl) 2014-09-17 2019-07-31 Oncodesign S.A. Makrocykliczne inhibitory kinazy lrrk2
MX2019007803A (es) 2016-12-28 2019-08-29 Dart Neuroscience Llc Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2).
ES2902365T3 (es) 2017-11-27 2022-03-28 Dart Neuroscience Llc Compuestos de furanopirimidina sustituidos como inhibidores de PDE1
CN117865965B (zh) * 2024-01-08 2024-06-28 贵州省天然产物研究中心 吡咯并嘧啶-4-胺和吡唑并嘧啶-4-胺衍生物及制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2818676A1 (de) * 1978-04-27 1979-11-08 Troponwerke Gmbh & Co Kg Substituierte 5,6-dimethylpyrrolo 2,3-d pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4213977A (en) * 1978-11-20 1980-07-22 Sterling Drug Inc. Pituitary-adrenal inhibiting method
DE3145287A1 (de) * 1981-11-14 1983-05-19 Troponwerke GmbH & Co KG, 5000 Köln Pyrrolo (2.3-d)pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
CA2100863A1 (en) * 1991-01-23 1992-07-24 David A. Bullough Adenosine kinase inhibitors
WO1994013676A1 (en) * 1992-12-17 1994-06-23 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
US5712303A (en) * 1992-12-17 1998-01-27 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists

Also Published As

Publication number Publication date
CA2170700A1 (en) 1996-09-03
CA2170700C (en) 1999-07-27
CN1141297A (zh) 1997-01-29
NZ286103A (en) 2000-08-25
EP0729758A2 (de) 1996-09-04
AU4585996A (en) 1996-09-12
AU715380B2 (en) 2000-02-03
KR960033454A (ko) 1996-10-22
IL117229A0 (en) 1996-06-18
CN1065535C (zh) 2001-05-09
EP0729758A3 (de) 1997-10-29
MX9600832A (es) 1997-02-28
IL117229A (en) 2003-02-12
JPH08259567A (ja) 1996-10-08
MY140557A (en) 2009-12-31

Similar Documents

Publication Publication Date Title
ZA961696B (en) Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders.
HUP9900330A3 (en) Pyrrolopyrimidines and processes for the preparation thereof
IL133800A0 (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
HUP9900508A3 (en) Use of 4-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene for prophylaxis and treatment of sequelae of reduced circulation in the brain and neurodegenerative disorders
GR980300033T1 (en) Compositions for the treatment of dermatological disorders and methods for their use
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
ZA966240B (en) Methods for treatment of allergic asthma.
PL322647A1 (en) Application of derivatives of imidazo [1,2-a] pyridino -3- acetamide in treating neuropsychiatric syndroms associated with disorders in functioning of neuronal circuits in the base of the brain
AU6615196A (en) Use of mp52 or mp121 for treating and preventing diseases of the nervous system
GB9519033D0 (en) Treatment
AU1578295A (en) Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
PL332313A1 (en) Application of benzopyranoles in treatment of neurological disorders
AU4517096A (en) The treatment of autoimmune disease using 2-amino purine derivatives
AU3539795A (en) Methods of treating cold symptoms using pentoxifylline
HUP9902802A3 (en) Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
GB9518887D0 (en) Treatment of muscular disorders
ZA984432B (en) Use of low-molecular-weight heparins for the prevention and treatment of trauma of the central nervous system
EP0893123A4 (de) Mittel zur behandlung und vorbeugung von altersbedingten krankheiten
ZA985818B (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders.
HUP9800272A3 (en) Use of penciclovir for the treatment of human herpes-virus-8
ZA9610264B (en) Preparation for use in the treatment of skin disorders.
AU6217694A (en) Use of triazine compounds for the treatment of memory and learning disorders
AU3205295A (en) Antisense oligonucleotides and methods for the treatment of schistosomiasis
EP0596937A4 (de) Plasmalopsychosine und plasmalocerebroside und verfahren zur behandlung von neuronalen erkrankungen mit diesen substanzen.